EU/3/05/324: Orphan designation for the treatment of nephrotic syndrome

Levamisole (hydrochloride)

Table of contents


On 28 October 2005, orphan designation (EU/3/05/324) was granted by the European Commission to ACE Pharmaceuticals BV, The Netherlands, for levamisol hydrochloride for the treatment of nephrotic syndrome.

Key facts

Active substance
Levamisole (hydrochloride)
Intended use
Treatment of nephrotic syndrome
Orphan designation status
EU designation number
Date of designation
ACE Pharmaceuticals BV
Schepenveld 41
3891 ZK Zeewolde
The Netherlands
Telephone: +31 36 522 72 01
Telefax: +31 36 522 9096

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating